Business
Theralase's Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study Research Presented at the American Urological Association
TORONTO, ON / ACCESSWIRE / May 6, 2019 / Theralase ® Technologies Inc. ('' Theralase...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase's Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study Research Presented at the American Urological AssociationTORONTO, ON / ACCESSWIRE / May 6, 2019 / Theralase® Technologies Inc. (''Theralase'' or the ''Company'') (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (''PDC'') and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce the Company's Anti-Cancer Therapy (''ACT'') for Non-Muscle Invasive Bladder Cancer (''NMIBC'') in a Phase Ib clinical study, was selected for presentation at the American Urological Association (''AUA'') conference, held in Chicago, Illinois on May 3rd to May 6th, 2019.The AUA is a premier urologic association, that provides invaluable support to the urologic community, with a mission to promote the highest standards of urological clinical care through education, research and the formulation of health care policy. The annual AUA conference brings together medical professionals and researchers from around the globe to discuss and present the latest advances in urological clinical care.At this year's AUA conference, Lother Lilge, Ph.D., Professor of Medical Biophysics at the University of Toronto, Senior Scientist at University Health Network (''UHN'') and a member of Theralase's Medical and Scientific Advisory Board presented, ''Improving the Safety and Efficacy of Photo Dynamic Therapy for NMIBC (Intravesical Ruthenium (II)-Photosensitizer and Light Dosimetry in a Phase 1b Clinical Trial)''.Dr. Lilge's presentation focused on the technology and science used by the Company to successfully complete the Phase Ib NMIBC Clinical Study (''Study''); specifically: the laser light emission and laser light detection utilized to safely and effectively destroy NMIBC.Shawn Shirazi, Ph.D., CEO - Drug Division, Theralase stated that, ''Human bladders come in a variety of shapes and sizes and the Company's ACT technology is able to automatically adjust the laser light delivered to the bladder wall in response to these differences through real-time laser light detection. This advanced ACT technology resulted in the Study demonstrating a 66% Complete Response (''CR''), for patients treated at the Therapeutic Dose (0.07 mg/cm2), up to 3...